Biotage Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biotage (STO:BIOT) Full Year 2024 Results

Key Financial Results

• Revenue: kr2.06b (up 10% from FY 2023).
• Net income: kr284.0m (up 15% from FY 2023).
• Profit margin: 14% (in line with FY 2023).
• EPS: kr3.55 (up from kr3.33 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biotage EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) exceeded analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Sweden.

Performance of the Swedish Life Sciences industry.

The company's shares are down 15% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Biotage that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.